Sequence Heterogeneity in the Core and NS5A Region of Hepatitis C Virus (HCV) and IL-28B Polymorphisms in Predicting Treatment Response among Chronic HCV Genotype 4 Infected Egyptian Patients

Background & Aims: Treatment plan of chronic HCV infection has dramatically improved after the introduction of different groups of Direct-Acting Antiviral (DAA) drugs. These drugs have been found to be safe and effective. Sofosbuvir (SOF) plus simeprevir (SMV) regimen has been shown to be tolerable and effective in treatment of patients with HCV genotype 1. The aim of the study was to evaluate the safety and the efficacy of combined sofosbuvir plus simeprevir treatment in genotype 4 chronic HCV patients. Methods: This open-label multicenter prospective study was carried out on 381 Egyptian patients with chronic hepatitis C virus- infection. Treatment experienced and treatment-naive patients were included. Subjects administrated a regimen of sofosbuvir (400 mg/ day) plus semiprevir (150 mg /day) for twelve weeks. Sustained Virological Response (SVR) was confirmed by undetectable HCV RNA by quantitative PCR 3 months after the end of the treatment. Results: 97.6% (372 /381) of patients had SVR. None of the studied clinical and demographic characteristics were associated with the SVR status. However, patients who failed to achieve SVR showed low albumin level and high total leucocyte. The most common side effects of the studied regimen were headache, fatigue, itching, photosensitivity, and cough. Conclusion: Twelve weeks’ regimen of sofosbuvir plus simeprevir was considered to be safe and tolerable in the treatment of HCV genotype 4; also it was associated with high SVR (97.6%).

Download Full-text

Hepatitis C virus genotype 3a: Predictive factors associated with treatment response in patients of Peshawar.

The Professional Medical Journal ◽

10.29309/tpmj/2019.26.08.3876 ◽

2019 ◽

Vol 26 (08) ◽

pp. 1315-1322

Author(s):

Amina Gul ◽

Naheed Gul ◽

Ijaz Ali ◽

Jawad Ahmed

Keyword(s):

Hepatitis C Virus ◽

Viral Load ◽

Hepatitis C ◽

Treatment Response ◽

Virological Response ◽

Baseline Viral Load ◽

P Value ◽

Hcv Genotype ◽

Chronic Hcv ◽

Genotype 3A

Hepatitis C Virus (HCV) is a flavivirus responsible for causing chronic liver diseases including cirrhosis and hepatocellular carcinoma. Identification of various patient and virus-related factors that can help predict response to antiviral therapy is extremely important in formulating the best therapeutic strategy for each patient either to continue or stop the therapy. The present study aimed to determine Sustained Virological Response (SVR) in HCV genotype 3a infected patients that received combination therapy of Sofosbuvir and Ribavirin and to investigate various factors that can help predict SVR. Study Design: Longitudinal Study Settings: Institute of basic Medical Sciences, Khyber Medical University, Peshawar (IBMS, KMU). Period: July 2016 to September 2017. Materials and Methods: Treatment response was evaluated among 100 HCV genotype 3a infected patients that received Sofosbuvir and Ribavirin therapy for 24 weeks. Various baseline parameters including hematological, biochemical and viral profiles of were recorded. HCV genotype determination was carried out by type specific nested PCR based genotyping assay. Viral load was determined at baseline, at 12 weeks for Early Virological Response (EVR) and at 24 weeks of treatment for SVR. Viral RNA quantification was carried out by Real Time PCR. Results: Out of 100 patients, SVR was observed in 83% of patients; while 17% of the chronic HCV 3a infected patients were Non-Responders (NR). Mean age of patients was low 34 ± 9.8 among patients who achieved SVR as compared to patients with non-response (41 ± 10). The 24 weeks Alanine aminotransferase (ALT) levels were significantly lower among patients with SVR (p-value ≤ 0.05). Although statistically not significant, baseline viral load was higher in NR group (p-value ≥ 0.05), than those with SVR. Association of EVR with SVR was found statistically significant (OR= 2.8, 95% CI 1.2-6.4, p-value ≤ 0.05). Conclusions: The current study indicated that pre and on-treatment monitoring of patients receiving anti-viral therapy is important for the management of patients with chronic HCV infection.

Download Full-text

Insulin resistance: a predictor for response to interferon-based therapy in Egyptian patients with chronic HCV genotype 4

Comparative Clinical Pathology ◽

10.1007/s00580-012-1560-0 ◽

2012 ◽

Vol 23 (1) ◽

pp. 7-13

Author(s):

Sherif Mogawer ◽

Mona Mansour ◽

Mohamed Marie ◽

Mervat El-Ansary ◽

Samah Abd El-Hamid

Keyword(s):

Insulin Resistance ◽

Genotype 4 ◽

Hcv Genotype ◽

Egyptian Patients ◽

Chronic Hcv

Download Full-text

The hepatitis C virus NS5A protein and response to interferon α: mutational analyses in patients with chronic HCV genotype 3a infection from India

Medical Microbiology and Immunology ◽

10.1007/s00430-006-0024-z ◽

2006 ◽

Vol 196 (1) ◽

pp. 11-21 ◽

Cited By ~ 7

Author(s):

Ankur Goyal ◽

Wolf P. Hofmann ◽

Eva Hermann ◽

Stella Traver ◽

Syed S. Hissar ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Interferon Α ◽

Hcv Genotype ◽

Ns5a Protein ◽

Chronic Hcv ◽

Genotype 3A

Download Full-text

IL‐28β gene polymorphism determines virological response to PEGylated interferon therapy in hepatitis C virus genotype 4 Egyptian patients

Journal of Cellular Biochemistry ◽

10.1002/jcb.28096 ◽

2018 ◽

Vol 120 (5) ◽

pp. 8154-8159 ◽

Cited By ~ 2

Author(s):

Nashwa El‐Khazragy ◽

Naglaa El Sayed ◽

Ahmed M. Salem ◽

Nahla S. Hassan ◽

Amal Tohamy Abdelmoeaz ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Gene Polymorphism ◽

Virological Response ◽

Interferon Therapy ◽

Pegylated Interferon ◽

Virus Genotype ◽

Genotype 4 ◽

Egyptian Patients

Download Full-text

Immunoglobulin M reactivity towards the inununologically active region sp75 of the core protein of hepatitis C virus (HCV) in chronic HCV infection

Journal of Medical Virology ◽

10.1002/jmv.1890390412 ◽

1993 ◽

Vol 39 (4) ◽

pp. 325-332 ◽

Cited By ~ 28

Author(s):

U. B. Hellström ◽

S. P. E. Sylvan ◽

R. H. Decker ◽

A. Sönnerborg

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Active Region ◽

Core Protein ◽

Immunoglobulin M ◽

Hcv Infection ◽

The Core ◽

Chronic Hcv Infection ◽

Chronic Hcv

Download Full-text

Body mass index (BMI) and alpha-fetoprotein (AFP) level correlate with the severity of HCV-induced fibrosis in a cohort of Egyptian patients with chronic HCV

Future Journal of Pharmaceutical Sciences ◽

10.1186/s43094-020-00085-3 ◽

2020 ◽

Vol 6 (1) ◽

Author(s):

Amal Ahmed Mohamed ◽

Amr Ali Hemeda ◽

Ramy Karam Aziz ◽

Mohamed Salaheldin Abdel-Hakeem ◽

Marwa Ali-Tammam

Keyword(s):

Body Mass Index ◽

Hepatitis C ◽

Liver Fibrosis ◽

Body Mass ◽

Alpha Fetoprotein ◽

Hcv Infection ◽

Hcv Genotype ◽

Egyptian Patients ◽

Chronic Hcv ◽

Severe Fibrosis

Abstract Background Viral hepatitis is the seventh leading cause of mortality globally, and half of this mortality is attributed to hepatitis C virus (HCV). Egypt has the highest HCV prevalence worldwide, with an estimated 14.7% of the population being HCV-positive. HCV infection is the primary cause of liver fibrosis, cirrhosis, and hepatocellular carcinoma. Liver fibrosis varies in severity during chronic HCV infection, and 10–20% of chronic hepatitis C (CHC) patients with severe fibrosis develop cirrhosis. The goal of this work was to assess the clinico-demographic predictors of severity of HCV-induced fibrosis in a cohort of Egyptian patients. Results A cohort of Egyptian patients with chronic HCV genotype 4a infection showed significant association between severe fibrosis stages and obesity, represented by a higher body mass index (BMI), low albumin level, high alpha-fetoprotein (AFP) level, low thyroid-stimulating hormone (TSH) level, and high alkaline phosphatase (ALP) level. Multivariate analysis delineated BMI, TSH, and ALP as independent significant variables that could predict the risk of fibrosis severity in HCV infections. Conclusion This study argues in favor of using the biomarker profile of CHC patients infected with HCV genotype 4a to identify patients at higher risk of developing severe fibrosis, which is a necessary first step towards precision medicine via patient stratification.

Download Full-text